000 01371 a2200397 4500
005 20250514053313.0
264 0 _c20030109
008 200301s 0 0 eng d
022 _a0022-5347
024 7 _a10.1016/S0022-5347(05)64093-1
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aAsahi, Hideki
245 0 0 _aBisphosphonate therapy for hormone refractory prostate cancer with bone metastasis.
_h[electronic resource]
260 _bThe Journal of urology
_cJan 2003
300 _a281-2 p.
_bdigital
500 _aPublication Type: Case Reports; Journal Article
650 0 4 _aAdenocarcinoma
_xblood
650 0 4 _aAged
650 0 4 _aAntineoplastic Agents, Hormonal
_xtherapeutic use
650 0 4 _aBone Neoplasms
_xblood
650 0 4 _aDiphosphonates
_xtherapeutic use
650 0 4 _aDrug Resistance, Neoplasm
650 0 4 _aDrug Therapy, Combination
650 0 4 _aEstramustine
_xtherapeutic use
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aProstate-Specific Antigen
_xblood
650 0 4 _aProstatic Neoplasms
_xblood
700 1 _aMizokami, Atushi
700 1 _aMaeda, Yuji
700 1 _aKomatsu, Kazuto
700 1 _aKoshida, Kiyoshi
700 1 _aNamiki, Mikio
773 0 _tThe Journal of urology
_gvol. 169
_gno. 1
_gp. 281-2
856 4 0 _uhttps://doi.org/10.1016/S0022-5347(05)64093-1
_zAvailable from publisher's website
999 _c12282884
_d12282884